Art

J-GLOBAL ID：202002275085565841   Reference number：20A0795880

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

新たに診断された血管内大細胞型B細胞リンパ腫(PRIMEUR-IVL)に対する高用量メトトレキサート+髄腔内化学療法と併用したリツキシマブ,シクロホスファミド,ドキソルビシン,ビンクリスチンおよびプレドニゾロン:多施設,単腕,第2相試験【JST・京大機械翻訳】

Author (35)： Shimada Kazuyuki (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Yamaguchi Motoko (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan) ,  Atsuta Yoshiko (Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan) ,  Matsue Kosei (Division of Hematology/Oncology, Internal Medicine, Kameda Medical Center, Kamogawa, Japan) ,  Sato Keijiro (Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan) ,  Kusumoto Shigeru (Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan) ,  Nagai Hirokazu (Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan) ,  Takizawa Jun (Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan) ,  Fukuhara Noriko (Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan) ,  Nagafuji Koji (Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan) ,  Miyazaki Kana (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan) ,  Ohtsuka Eiichi (Department of Hematology, Oita Prefectural Hospital, Oita, Japan) ,  Okamoto Masataka (Department of Hematology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan) ,  Sugita Yasumasa (Department of Hematology, Oami Municipal Hospital, Oamishirasato, Japan) ,  Uchida Toshiki (Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan) ,  Kayukawa Satoshi (Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan) ,  Wake Atsushi (Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan) ,  Ennishi Daisuke (Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan) ,  Kondo Yukio (Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan) ,  Izumi Tohru (Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan) ,  Kin Yoshihiro (Department of Hematology, Daini Osaka Police Hospital, Osaka, Japan) ,  Tsukasaki Kunihiro (Department of Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan) ,  Hashimoto Daigo (Department of Hematology, Hokkaido University Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan) ,  Yuge Masaaki (Division of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan) ,  Yanagisawa Atsumi (Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan) ,  Kuwatsuka Yachiyo (Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan) ,  Kuwatsuka Yachiyo (Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan) ,  Shimada Satoko (Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan) ,  Masaki Yasufumi (Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Japan) ,  Niitsu Nozomi (International Medical Center, Saitama Medical University, Hidaka, Japan) ,  Kiyoi Hitoshi (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Suzuki Ritsuro (Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan) ,  Tokunaga Takashi (Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan) ,  Nakamura Shigeo (Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan) ,  Kinoshita Tomohiro (Division of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 21  Issue： 4  Page： 593-602  Publication year： 2020 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Intravascular large B-cell lym...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0795880&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： testis ,  Death ,  *lymphoma ,  survival ratio ,  2 stroke cycle ,  Neutropenia ,  repeated administration ,  *phase 2 study ,  R-CHOP therapy ,  end point ,  adverse reaction ,  indole alkaloid ,  amine ,  nitrogen heterocyclic compound ,  oxygen heterocyclic compound ,  organochlorine compound ,  inorganic acid ester ,  phosphorus heterocyclic compound ,  amino sugar ,  quinone ,  glycoside (except carbohydrate) ,  polyphenol ,  deoxysugar ,  pyranoside ,  phenol ether ,  polynuclear aromatic compound ,  hydroxy ketone ,  polyol
Semi thesaurus term： *リツキシマブ ,  有害事象 , 【Automatic Indexing@JST】

JST classification (3)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical oncology in general  (GE03010Y)

Substance index (3)： Vincristine ,  Cyclophosphamid ,  Doxorubicin

Terms in the title (13)： 診断 ,  血管内大細胞型B細胞リンパ腫 ,  高用量メトトレキサート ,  髄腔内化学療法 ,  併用 ,  リツキシマブ ,  シクロホスファミド ,  ドキソルビシン ,  ビンクリスチン ,  プレドニゾロン ,  施設 ,  腕 ,  第2相試験